Robert Barrow, MindMed CEO

FDA slams clin­i­cal hold on tiny psy­che­delics play­er's shot at bring­ing LSD-as­sist­ed ther­a­py to more pa­tients

Psy­che­del­ic ther­a­py has emerged once again as a po­ten­tial­ly promis­ing path to treat­ing neu­ro­log­i­cal con­di­tions, but one tiny biotech is now fac­ing a holdup at the FDA in bring­ing its LSD pro­gram to more pa­tients.

The FDA has slammed a clin­i­cal hold on MindMed’s IND ap­pli­ca­tion for a Phase IIb study test­ing its LSD-as­sist­ed ther­a­py in pa­tients with gen­er­al­ized anx­i­ety dis­or­der, the biotech said Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.